U.S. markets closed
  • S&P 500

    3,640.47
    -78.57 (-2.11%)
     
  • Dow 30

    29,225.61
    -458.13 (-1.54%)
     
  • Nasdaq

    10,737.51
    -314.13 (-2.84%)
     
  • Russell 2000

    1,674.93
    -40.31 (-2.35%)
     
  • Crude Oil

    81.61
    -0.54 (-0.66%)
     
  • Gold

    1,668.80
    -1.20 (-0.07%)
     
  • Silver

    18.80
    -0.08 (-0.45%)
     
  • EUR/USD

    0.9816
    +0.0077 (+0.80%)
     
  • 10-Yr Bond

    3.7470
    +0.0420 (+1.13%)
     
  • GBP/USD

    1.1119
    +0.0234 (+2.15%)
     
  • USD/JPY

    144.4400
    +0.3180 (+0.22%)
     
  • BTC-USD

    19,498.28
    -50.24 (-0.26%)
     
  • CMC Crypto 200

    444.40
    -1.58 (-0.35%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration

·1 min read

Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.

  • The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD).

  • Sixty-six participants (18%) with Polypoidal Choroidal Vasculopathy (PCV) out of a total study population of 366 were included in the analysis.

  • OPT-302 combination therapy had a safety profile consistent with the standard of care anti-VEGF-A monotherapy while demonstrating greater improvements in best-corrected visual acuity (BCVA) and less retinal fluid than ranibizumab monotherapy.

  • The +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy over ranibizumab (p = 0.0253) was accompanied by a greater improvement in secondary vision and anatomical outcome measures at week 24.

  • Price Action: OPT shares closed at $6.65 on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.